RecruitingPhase 2NCT05551208

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

Studying Malignant epithelial tumor of ovary

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chongqing University Cancer Hospital
Principal Investigator
Zou Dongling, M.D., MD PhD FACP
Chongqing University Cancer Hospital
Intervention
fluzopanib and bevacizumab(drug)
Enrollment
42 enrolled
Eligibility
18-75 years · FEMALE
Timeline
20222029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05551208 on ClinicalTrials.gov

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

See all trials for Malignant epithelial tumor of ovary

← Back to all trials